The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Docetaxel with androgen deprivation therapy (ADT) and radiotherapy (RT) for high-risk localized prostate cancer (HRLPC): An ICECaP individual patient-data (IPD) meta-analysis of randomized controlled trials (RCTs).
 
Praful Ravi
Consulting or Advisory Role - Bayer
Research Funding - Bayer (Inst); Lantheus Medical Imaging (Inst); Lilly (Inst); Novartis (Inst); Telix Pharmaceuticals (Inst)
 
Lucia Kwak
No Relationships to Disclose
 
Wanling Xie
Consulting or Advisory Role - Convergent Therapeutics; Prostate Cancer Clinical Trial Consortium
 
Anthony D'Amico
No Relationships to Disclose
 
James Dignam
No Relationships to Disclose
 
Karim Fizazi
Honoraria - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Novartis (Inst)
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo Europe GmbH (Inst); Janssen Oncology (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Janssen; MSD; Novartis; Pfizer
 
Nicholas James
Honoraria - Astellas Pharma; Bayer; Janssen; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Clovis Oncology; EUSA pharma; Janssen; pfizer; Sanofi
Speakers' Bureau - Astellas Pharma; AstraZeneca; Ferring; Janssen Oncology; Merck; Pierre Fabre; Sanofi
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Janssen (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bayer; Janssen; Sanofi
 
Gwenael Le Teuff
No Relationships to Disclose
 
Paul Nguyen
Stock and Other Ownership Interests - Nanocan Therapeutics; Reversal Therapeutics; Stratagen Bio
Consulting or Advisory Role - Bayer; Boston Scientific; Janssen; Nanocan Therapeutics; Novartis
Research Funding - Astellas Oncology (Inst); Bayer (Inst); Janssen (Inst)
 
Howard Sandler
Consulting or Advisory Role - Janssen
Other Relationship - Caribou Publishing
 
Alton Sartor
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; ARTbio; BioNTech SE; Cardinal Health; Clarity Pharmaceuticals; Convergent Therapeutics; Lilly; Perspective; Ratiopharm; Telix Pharmaceuticals; United Health Group
Honoraria - Actinium Pharmaceuticals; Advancell; AstraZeneca; Clarity Pharmaceuticals; Convergent Therapeutics; Intellisphere; Lantheus Medical Imaging; Pfizer; Point Therapeutics; Ratiopharm; Sanofi; Telix Pharmaceuticals
Consulting or Advisory Role - Actinium Pharmaceuticals; Advancell; Amgen; ARTbio; Astellas Pharma; AstraZeneca; Bayer; Clarity Pharmaceuticals; Fusion Pharmaceuticals; Isotopen Technologien; Janssen; Lantheus Medical Imaging; Novartis; Pfizer; Point Biopharma; Ratiopharm; Sanofi; Telix Pharmaceuticals; Telix Pharmaceuticals
Research Funding - AstraZeneca (Inst); Bayer (Inst); InVitae (Inst); Janssen; Lantheus Medical Imaging (Inst); Merck (Inst); Novartis (Inst); POINT Biopharma (Inst); Sanofi (Inst)
Expert Testimony - Sanofi
Travel, Accommodations, Expenses - Bayer; Lantheus Medical Imaging; Sanofi
 
Matthew Sydes
Honoraria - AstraZeneca; Eisai; Janssen
Research Funding - Astellas Pharma (Inst); Janssen-Cilag (Inst)
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Cadence Pharma; CellCentric; Genentech/Roche; Janssen Biotech; Lilly; Pfizer; POINT Biopharma
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Pfizer (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination